Dave Simpson
Chief Executive Officer Iksuda Therapeutics
Dave founded IKSUDA Therapeutics in 2012 and has >25 years of experience in Biotech & Pharma, primarily in the development & commercialization of biotherapeutics.
IKSUDA, now a clinical stage ADC company is focussed on the development of FIC/BIC class ADCs by deploying enabling chemistry platforms and Known/Novel payloads to address the challenges of haematological and solid cancers.
Previously, Dave established Eden Biodesign – a CDMO service to biotech clients across the world. Acquired by Watson Pharmaceuticals in 2010, Dave led several Biosimilar programs through clinical/commercial development.
Seminars
Tuesday 9th March 2027
CEO & ADC Pharma Leaders Think Tank: Solidifying Next Generation ADCs as Standard of Care Therapies
9:30 am
- Understanding the 2027 ADC landscape and how the bar has been raised to develop and deliver ADCs with meaningful patient impact
- Outlining the future opportunities and applications on the horizon for ADCs to achieve target differentiation and clinical safety
- Highlighting methods to best pursue ADC clinical differentiation across patient selection technologies, combination strategies, and well-executed clinical design
- With clinical trials advancing in the Far East and Australia, what opportunities does this open for the ADC industry to progress faster?
